Teva- Pharmaceutical Industries Operating Income

As of the most recent data (June 2026), TEVA shows a operating income of $2B. That compares with $890M in the prior-year period — up 121.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TEVA's operating income is now $2B (was $890M) — a 121.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Teva- Pharmaceutical Industries is outperforming or lagging.

Tracking TEVA's operating income over time shows whether Teva- Pharmaceutical Industries is scaling, shrinking, or reshaping that part of the business. The current reading is $2B That compares with $890M in the prior-year period — up 121.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Teva- Pharmaceutical Industries's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $2B) with ownership activity and broader fundamentals.

Teva- Pharmaceutical Industries's operating income is $2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.